CTLA4 (Cytotoxic T-Lymphocyte Antigen 4)
CTLA4
Immune checkpoint receptor that negatively regulates T cell activation at the priming stage.
Funktion
CTLA-4 blockade (ipilimumab) enhances T cell activation. First checkpoint inhibitor approved for melanoma.
Arzneimittel, die auf dieses Target wirken
| Arzneimittel | Wirkung | Primär |
|---|---|---|
| Pembrolizumab | Other | — |
Related Targets
OPRM1 (Mu-Opioid Receptor)
OPRM1
PDCD1 (Programmed Cell Death Protein 1)
PDCD1
SIGMAR1 (Sigma-1 Receptor)
SIGMAR1
AGTR1 (Angiotensin II Type 1 Receptor)
AGTR1
ADRB1 (Beta-1 Adrenergic Receptor)
ADRB1
ADRB2 (Beta-2 Adrenergic Receptor)
ADRB2
DRD2 (Dopamine D2 Receptor)
DRD2
HRH2 (Histamine H2 Receptor)
HRH2